First Citizens Bank & Trust Co. lowered its holdings in Celgene Co. (NASDAQ:CELG) by 88.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,448 shares of the biopharmaceutical company’s stock after selling 25,297 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Celgene were worth $325,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of CELG. Bruderman Asset Management LLC acquired a new stake in shares of Celgene in the fourth quarter valued at $25,000. Murphy Pohlad Asset Management LLC acquired a new stake in shares of Celgene in the fourth quarter valued at $25,000. Athena Capital Advisors LLC acquired a new stake in shares of Celgene in the fourth quarter valued at $27,000. Liberty Wealth Management LLC acquired a new stake in shares of Celgene in the fourth quarter valued at $29,000. Finally, Berman Capital Advisors LLC acquired a new stake in shares of Celgene in the fourth quarter valued at $32,000. Institutional investors own 74.81% of the company’s stock.
Celgene stock opened at $94.55 on Wednesday. Celgene Co. has a fifty-two week low of $58.59 and a fifty-two week high of $95.44. The company has a quick ratio of 2.12, a current ratio of 2.23 and a debt-to-equity ratio of 3.21. The stock has a market capitalization of $66.80 billion, a PE ratio of 12.42, a PEG ratio of 0.43 and a beta of 1.71.
A number of equities research analysts have recently weighed in on the company. Mizuho set a $103.00 price objective on Celgene and gave the company a “buy” rating in a research note on Friday, April 5th. Cantor Fitzgerald reissued a “buy” rating and set a $100.00 target price on shares of Celgene in a research note on Thursday, January 3rd. Goldman Sachs Group raised Celgene from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $71.00 to $88.00 in a research note on Thursday, January 3rd. Jefferies Financial Group cut Celgene from a “buy” rating to a “hold” rating and set a $95.00 target price for the company. in a research note on Friday, February 1st. Finally, William Blair cut Celgene from an “outperform” rating to a “market perform” rating in a research note on Monday, April 1st. One investment analyst has rated the stock with a sell rating, eighteen have given a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $99.41.
In other Celgene news, Director James J. Loughlin sold 23,466 shares of the company’s stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the completion of the sale, the director now directly owns 62,102 shares of the company’s stock, valued at approximately $5,420,883.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ernest Mario acquired 2,000 shares of Celgene stock in a transaction on Tuesday, February 12th. The shares were bought at an average cost of $89.99 per share, with a total value of $179,980.00. The disclosure for this purchase can be found here. 0.39% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Celgene Co. (CELG) Shares Sold by First Citizens Bank & Trust Co.” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/17/celgene-co-celg-shares-sold-by-first-citizens-bank-trust-co.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
See Also: Earnings Reports
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.